April 5-6, 2021 Webconference
The Longwood Healthcare Leaders meeting, April 5-6, 2021, is centered on MIT’s Koch Institute via webconference with leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp
Speakers include FDA CDER Director Janet Woodcock, GSK R&D head Hal Barron, Regeneron CSO George Yancopoulos, Janssen Global R&D head Mathai Mammen, Sanofi R&D head John Reed, Genentech CEO Alexander Hardy, Novartis Institutes for BioMedical Research President Jay Bradner, Takeda R&D head Andy Plump, AbbVie Chief Strategy Officer Henry Gosebruch, Merck Chief Patient Officer and former CDC Director Julie Gerberding, BMS R&D head Rupert Vessey, Moderna CSO Melissa Moore, Alexion R&D head John Orloff, AbbVie R&D head Tom Hudson, Amgen R&D head David Reese, BIO Chair Jeremy Levin, among others.
These meetings are focused on accelerating the translation of discoveries into medicines to help patients; substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities.
LONGWOOD HEALTHCARE LEADERS | APRIL 5-6, 2021
​
MONDAY, APRIL 5, 2021 | AGENDA
-- all times Eastern Standard –
​
7:30 – 8:00 | LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund; Rich Aldrich, General Partner, Longwood Fund; David Steinberg, General Partner, Longwood Fund; John Lawrence, CFO, Longwood Fund
8:00 – 8:20 | MANAGING HEALTH SYSTEMS IN A NEW ERA
Tom Sequist, Chief Patient Experience & Equity Officer, Mass General Brigham; Kevin Tabb, CEO, Beth Israel Lahey
Moderator: David Steinberg, General Partner, Longwood Fund
8:20 – 8:50 | STRATEGY IMPLEMENTATION: FROM NEWCO TO ESTABLISHED
Jeff Goldberg, CEO, Immunitas; Robert Sims, EIR, Third Rock; David Southwell, CEO, TScan Therapeutics; Lara Sullivan, CEO, Pyxis Oncology; K. Dane Wittrup, Professor, Chemical & Biological Engineering, Koch Institute
Moderator: Connie Chiang, Managing Director, Barclays Bank
8:50 – 9:20 | A NEW ERA OF COLLABORATION AND ENHANCED TRANSPARENCY
Percival Barretto-Ko, CBO, Astellas Pharma; Julie Gerberding, Chief Patient Officer, Merck & Co., former Director, CDC; Joanne Waldstreicher, CMO, Johnson & Johnson
Moderator: John Westwood, Managing Partner, Huron Consulting Group
9:20 – 9:50 | INNOVATION IN THE ROLE OF MANUFACTURING
Nabiha Saklayen, CEO, Cellino; Jason Kelly, CEO, Ginkgo Bioworks; Rahul Singhvi, CEO, Resilience; Mark Stevenson, COO, Thermo Fisher Scientific
Moderator: JC Gutierrez-Ramos, SVP & CSO, Danaher Corporation
9:50 – 10:20 | EXPEDITING RESEARCH FOR TREATMENTS AND CURES
Charles Albright, CSO, Affinia Therapeutics; Jessica Grossman, CEO, IgGenix; Brad Margus, CEO, Cerevance; Rich Moscicki, EVP, Science & Regulatory Advocacy, CMO, PhRMA; Rogerio Vivaldi, CEO, Sigilon
Moderator: George Daley, Dean, Harvard Medical School
10:20 – 10:50 | FIRESIDE CHAT
Alexander Hardy, CEO, Genentech; Emmanuel Ligner, CEO, Cytiva
Moderator: David Steinberg, General Partner, Longwood Fund
10:40 – 11:10 | IDENTIFYING NOVEL TECHNOLOGY
Rafael Amado, EVP, Head of R&D & CMO, Allogene; Maria Fardis, CEO, Iovance; Brett Monia, CEO, Ionis Pharmaceuticals; Alan Sachs, CSO, Thermo Fisher Scientific; Tarek Samad, CSO, Immunitas
Moderator: Michal Preminger, Head, E. North America, Johnson & Johnson Innovation
11:10 – 11:30 | FIRESIDE CHAT
Mathai Mammen, Global Head, R&D, Janssen; George Yancopoulos, President & CSO, Regeneron, Tal Zaks, CMO, Moderna
Moderator: Christoph Westphal, General Partner, Longwood Fund
11:30 – 12:00 | THE EVOLVING NEEDS OF R&D
Hal Barron, Head, R&D, GlaxoSmithKline; Jay Bradner, President, Novartis Institutes for BioMedical Research; Aakanksha Khandelwal, Head, Global Portfolio Strategy & Innovation, EMD Serono; Frank Nestle, Global Head, Research, CSO, Sanofi
Moderator: Ray Deshaies, Head, Global Research, Amgen
12:00 – 12:20 | FIRESIDE CHAT
Levi Garraway, CMO, Roche; John Maraganore, CEO, Alnylam; Janet Woodcock, Commissioner, FDA
Moderator: Christoph Westphal, General Partner, Longwood Fund
12:20 – 12:50 | ALTERNATIVE SOURCES OF FUNDING
Mike Boyle, CEO, Cystic Fibrosis Foundation; Sophie Kornowski, Senior Partner, Gurnet Point Capital; Paul Lammers, CEO, Triumvira; Stephen Lesser, Vice President, NovaQuest
Moderator: Bill Hicks, Co-Chair, Securities & Capital Markets Practice, Mintz
12:50 – 1:20 | GOING GLOBAL: WORKING ACROSS INTERNATIONAL MARKETS
Thierry Bernard, CEO, Qiagen; Aoife Brennan, CEO, Synlogic; Ivan Cheung, Chair & CEO, Eisai US; Björn Frendéus, CSO, BioInvent; Trish Hurter, CEO, Lyndra
Moderator: Stephen Uden, Co-Founder, RallyBio
1:20 – 1:50 | TAPPING INTO INNOVATION: BIOPHARMA HUBS
John Flavin, CEO, Portal Innovations; Joel Marcus, Chair, Alexandria Real Estate; Lloyd Minor, Dean, Stanford School of Medicine; Lizzie Ngo, Senior Associate, Longwood Fund; Iskra Reic, EVP, Europe & Canada, AstraZeneca
Moderator: Chandra Ramanathan, Global Head, Pharma R&D, Open Innovation, Bayer
1:50 – 2:20 | DIVERSITY, INCLUSION, AND EQUITY IN BIOPHARMA
Alisha Alaimo, President, US, Biogen; Charlotte Jones-Burton, VP, Global Clinical Development, Nephrology, Otsuka Pharmaceuticals; Julie Kampf, CEO, JBK Associates; Lucy Liu, Senior Associate, Longwood Fund; Rob Perez, Founder & Chair, Life Science Cares
Moderator: Ron Cooper, CEO, Albireo Pharma
2:20 – 2:50 | DESIGNING THE DEAL
Phil McGurk, Head, East Coast BD & Acquisitions, AbbVie; Lonnie Moulder, Founding General Partner, Tellus BioVentures; Patrick Verheyen, Global Head, BD, Janssen; Jonathan York, VP, Global BD, Daiichi Sankyo
Moderator: Chad Shear, Principal, Fish & Richardson
2:50 – 3:10 | FIRESIDE CHAT
Andy Plump, President, R&D, Takeda; John Reed, EVP, Global Head, RD, Sanofi
Moderator: Christoph Westphal, General Partner, Longwood Fund
3:10 – 3:40 | NAVIGATING REGULATORY CHALLENGES
Dietmar Berger, CMO, Global Head, Development, Sanofi; PJ Brooks, Program Director, NIH; Priti Hegde, CSO, Foundation Medicine; Lynn Kramer, Chief Clinical Officer, Eisai; John Orloff, EVP, Head, R&D, Alexion
Moderator: Art Krieg, CSO, Checkmate Pharmaceuticals
3:40 – 4:10 | THE UPS, DOWNS, AND UPS OF DRUG APPROVAL
JJ Bienaime, CEO, BioMarin; Barry Greene, CEO, Sage Therapeutics; Ted Love, CEO, Global Blood Therapeutics; Bill Mezzanotte, EVP, Head, R&D & CMO, CSL Behring; Raquel Mura, Head, R&D North America, Sanofi
Moderator: Gaurav Shah, CEO, Rocket Pharmaceuticals
4:10 – 4:30 | FIRESIDE CHAT
Ruxandra Draghia-Akli, Global Head, Global Public Health R&D, Johnson & Johnson; JC Gutierrez-Ramos, SVP & CSO, Danaher Corporation
Moderator: David Steinberg, General Partner, Longwood Fund
4:30 – 5:00 | AFTER IPO: MAINTAINING MOMENTUM
Al Beardsley, COO, Galera Therapeutics; Sarah Boyce, CEO, Avidity Biosciences; Pablo Cagnoni, CEO, Rubius Therapeutics; Dan Omstead, CEO, Tekla Capital Management; Aaron Schwimmer, Managing Director, Barclays Bank
Moderator: Dan Paterson, COO & President, Verastem
5:00 – 5:10 | LONGWOOD FUND SUMMARY
Lea Hachigian, Venture Partner, Longwood Fund; Aleks Radovic-Moreno, Venture Partner, Longwood Fund; Christoph Westphal, General Partner, Longwood Fund
​
​
TUESDAY, APRIL 6, 2021
7:00 – 7:30 | LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund; Rich Aldrich, General Partner, Longwood Fund; David Steinberg, General Partner, Longwood Fund; John Lawrence, CFO, Longwood Fund
7:30 – 8:00 | PROGRESS TOWARDS SUSTAINABLE VACCINES FOR COVID-19
Stan Erck, CEO, Novavax; Melissa Moore, Chief Strategy Officer, Moderna; Ryan Richardson, Chief Strategy Officer, BioNTech; Derrick Sim, Director, Vaccine Supply & Demand, Gavi, The Vaccine Alliance
Moderator: Michael Mina, Asst. Professor, Epidemiology, Harvard School of Public Health
8:00 – 8:30 | NOVEL THERAPEUTIC MODALITIES
Al Gianchetti, CEO, XyloCor; Bill Hinshaw, CEO, Axcella Health; Sekar Kathiresan, CEO, Verve; Laura Sepp-Lorenzino, CSO, Intellia; Angela Shen, CMO, Arcellx
Moderator: Roger Tung, CEO, Concert Pharmaceuticals
8:30 – 8:50 | FIRESIDE CHAT
Tyler Jacks, Director, MIT Koch Institute for Integrative Cancer Research; Bob Langer, Co-Founder, Moderna/Momenta, Nobelist, NAS; Phil Sharp, Co-Founder, Biogen/Alnylam, Nobelist, NAS; Jonathan Weissman, Whitehead Institute, MIT, NAS
Moderator: Christoph Westphal, General Partner, Longwood Fund
8:50 – 9:20 | BIG BIOPHARMA R&D
Teri Foy, SVP, IO & Cellular Therapy, Bristol Myers Squibb; Steve Hitchcock, Head, Research, Takeda; Philip Larsen, Global Head, Research, Bayer Pharmaceuticals; Richard Staub, President, R&D Solutions, IQVIA
Moderator: Melinda Richter, Global Head, JLabs, Johnson & Johnson Innovation
9:20 – 9:50 | ENSURING DIAGNOSTIC ACCURACY AND EFFICIENCY
Joshua Ofman, CMO & External Affairs, Grail Bio; Mark Stevenson, COO, Thermo Fisher Scientific; David Walt, Professor, Biologically Inspired Engineering, Harvard Medical School
Moderator: Lea Hachigian, CEO, ImmuneID, Venture Partner, Longwood Fund
9:50 – 10:20 | DRIVING INNOVATION IN CELL THERAPY
Lea Hachigian, Venture Partner, Longwood Fund; Richard James, Associate Professor, University of Washington; Frances Eun-Hyung Lee, Associate Professor, Emory; David Rawlings, Director, Center for Immunity and Immunotherapies, Seattle Children's Research Institute; Jason Rhodes, Partner, Atlas Ventures
Moderator: Aleks Radovic-Moreno, Venture Partner, Longwood Fund
10:20 – 10:40 | FIRESIDE CHAT
Paul Anderson, Chief Academic Officer & SVP, Research, Brigham Health; Laurie Glimcher, CEO, Dana-Farber Cancer Institute
Moderator: David Steinberg, General Partner, Longwood Fund
10:40 – 11:10 | EXPEDITING THE PATH TO PATIENT CARE
Fiona Elwood, Head, Neuroscience, Novartis; Cedric Francois, CEO, Apellis; Eileen Maus, CEO, Renovia Inc; Maria Rivas, CMO, Merck KGaA; Clay Siegall, CEO, Seagen
Moderator: Jeremy Levin, CEO, Ovid Therapeutics
11:10 – 11:40 | LEVERAGING AI TO TRANSFORM DRUG DISCOVERY AND DEVELOPMENT
Jennifer Buell, President & CEO, Agenus; Annalisa D’Andrea, CSO, ImmuneID; Milind Kamkolkar, CDO, Cellarity; Brian Martin, Head, AI, AbbVie
Moderator: Robert Gentleman, Founding Executive Director, Center for Computational Biomedicine, Harvard Medical School
11:40 – 12:00 | FIRESIDE CHAT
David Reese, EVP, R&D, Amgen; Rupert Vessey, President, Research & Early Development, Bristol Myers Squibb
Moderator: Christoph Westphal, General Partner, Longwood Fund
12:00 – 12:30 | EXTERNAL INNOVATION
Diana Gallagher, Head, External Innovation & New Indications, Biogen; Roger Palframan, Head, External Innovation, UCB; Priyanka Rohatgi, Managing Director, Ventures, Ipsen; Bob Silverman, CBO, Alloy Therapeutics; Joanne Smith-Farrell, CEO, Be Bio
Moderator: Uwe Schoenbeck, CSO, External R&D, Pfizer
12:30 – 1:00 | MAKING A BIG IMPACT WITH LIMITED RESOURCES
Chris Garabedian, CEO, Xontogeny; Jeb Keiper, CEO, Nimbus Therapeutics; Martin Mackay, CEO, RallyBio; Adelene Perkins, CEO, Infinity Pharmaceuticals; Neil Weir, CEO, Sitryx
Moderator: David Meek, CEO, FerGene
1:00 – 1:30 | SCIENTIFIC INNOVATION: LAUNCHING COMPANIES FROM ACADEMIA
Omar Abudayyeh, Fellow, McGovern Institute; George Church, Professor, Harvard Medical School; Bill Hait, Global Head, External Innovation, Johnson & Johnson; Rachel Haurwitz, CEO, Caribou Biosciences; Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer institute
Moderator: Paul Schimmel, Professor, Cell & Molecular Biology, Scripps
1:30 – 1:50 | FIRESIDE CHAT
Francis deSouza, CEO, Illumina; Skip Virgin, CSO, Vir Biotechnology, NAS
Moderator: Christoph Westphal, General Partner, Longwood Fund
1:50 – 2:20 | ALIGNING PRIORITIES WITH THE BOARD
Anirvan Ghosh, CEO, Unity Biotechnology; Enoch Kariuki, BOD, Imago, Zentalis; Denitsa Milanova, CEO, Marble Therapeutics; Myrtle Potter, CEO, Sumitovant
Moderator: Ramani Varanasi, CEO, X-Biotix
2:20 – 2:50 | DIFFERENTIATION IN ONCOLOGY
Philip Astley-Sparke, CEO, Replimune; Axel Hoos, SVP, R&D Governance Chair & Head, Oncology, GlaxoSmithKline; Pearl Huang, CEO, Cygnal Therapeutics; Armon Sharei, CEO, SQZ Biotech; Zhen Su, SVP, Head, Global Oncology, Merck KGaA
Moderator: Teresa Bitteti, President, Oncology, Takeda
2:50 – 3:20 | INNOVATIVE PARTNERSHIPS
Henry Gosebruch, Chief Strategy Officer, AbbVie; Jennifer Giottonini Cayer, CBO, Pulmocide; Alban de La Sabliere, SVP, Global Head, Partnering, Sanofi; Doug Giordano, SVP, WWBD, Pfizer; Ioannis Sapountzis, Global Head, BD&L, Boehringer Ingelheim; Kimberly Smith, SVP, Head, R&D, ViiV Healthcare
Moderator: Kendra Rose, VP, Head New BD, Bayer Pharmaceuticals
3:20 – 3:40 | PERSPECTIVES ON HEALTHCARE REFORM AND PRICING
Peter Kolchinsky, Managing Director, RA Capital; Peter Rubin, Executive Director, No Patient Left Behind
3:40 – 4:15 | DEALS WITHIN THE VENTURE NETWORK
Eugene Chiu, Senior Partner, Investments, In-Q-Tel; Ansbert Gadicke, Managing Director, MPM Capital; Kyle Lefkoff, General Partner, Boulder Ventures; Bob Nelsen, Managing Director, ARCH Venture Partners; Aleks Radovic-Moreno, Venture Partner, Longwood Fund; Jeff Stevens, Principal, Alexandria Venture Investments
Moderator: Bryan Czyzewski, SVP, Jefferies Investment Banking
4:15 – 4:30 | LONGWOOD FUND SUMMARY
Aleks Radovic-Moreno, Venture Partner, Longwood Fund; David Steinberg, General Partner, Longwood Fund; Lizzie Ngo, Senior Associate, Longwood Fund
Supporters
We are grateful to the following organizations for their support of this meeting. To learn more about getting involved contact susan@longwoodfund.com
Barclays
Barclays is a transatlantic consumer and wholesale bank offering products and services across personal, corporate and investment banking, credit cards and wealth management, with a strong presence in our two home markets of the UK and the US. With over 325 years of history and expertise in banking, Barclays operates in over 40 countries and employs approximately 83,500 people. Barclays moves, lends, invests and protects money for customers and clients worldwide. For further information about Barclays, please visit our website www.barclays.com/ib
Cytiva
Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Formerly part of GE Healthcare Life Sciences, we have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020. Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes.
Fish & Richardson
Fish & Richardson, a premier global intellectual property (IP) law firm, works with pioneering life sciences companies to help them achieve their strategic IP goals through partnering, licensing, financing, acquisition, and enforcement. We do this by bringing a unique, holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP.
Huron
Biopharmaceutical and medical device companies remain under pressure to navigate ever-changing environments. We work with our clients to innovate and improve health outcomes while justifying product value. Huron’s life sciences business is part of Huron’s continuum of healthcare offerings supporting the development and commercialization of technologies in these companies.
Discover how Huron can help you to harness new developments and stay ahead of the curve.
• Corporate and Franchise Strategy
• Commercial Strategy
• R&D Strategy
• Business Development Strategy
• Market Access and Pricing
.jpg)
IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry dedicated to delivering actionable insights. Learn more at www.iqvia.com.
JBK
JBK Associates International is a woman-owned, global executive search firm that is a leader in the recruitment and retention of diverse talent across a wide spectrum of industries with exceptional depth in the Life Sciences. Our D&I expertise spans 19 years and supports our client's strategy for creating the most inclusive organizations with the greatest ROI. We bring great leaders to great companies. jbkassociates.net
Jeffries
.jpg){kind=logo}
Jefferies Group LLC is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly-owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.
Mintz
Mintz is a versatile Am Law 100 law firm with 500 attorneys serving clients worldwide. We collaborate across disciplines to deliver exceptional legal strategies that help clients navigate shifting industry challenges. Our attorneys advise business leaders, entrepreneurs, and investors on pivotal deals, disputes, and regulatory matters. We work within four core practice areas—Transactional, Intellectual Property, Litigation & Investigations, and Regulatory & Advisory—and serve industries including the life sciences; health care; technology; insurance & financial services; energy & sustainability; sports & entertainment; real estate, construction & infrastructure; retail & consumer products; and education & nonprofit sectors. Visit us at www.mintz.com.
Replimune
Replimune is pioneering a new class of oncolytic immunotherapies (OI) designed to ignite a powerful patient-specific immune response to treat cancer and vaccinate against future relapse. The company’s Immulytic™ platform is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver therapies with the ability to directly kill tumors and generate systemic anti-cancer immune responses. Since September 2015, Replimune has built a portfolio of product candidates with three programs currently in the clinic. Its lead program, RP1, is in two registration directed clinical trials – in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma-– and is also being tested in other tumor types, including anti-PD1 failed non-small cell lung cancer. Two further product candidates, RP2 and RP3, are currently in Phase 1 clinical development. Replimune has completed buildout of its 63,000-square-foot state-of-the-art GMP manufacturing facility which will support later-stage development and full commercialization of all of its products.